In the early 2000s, the cost of sequencing a human genome exceeded $1bn. This has now fallen to under $1,000. This rapid reduction in price has increased the adoption of genome sequencing across an array of scientific practices, including oncology and disease diagnosis. Illumina’s technology has already become the de-facto standard which underpins most of the clinical testing industry, and we believe that, in time, their tools will support the development of a whole host of new clinical applications.
Jay Flatley is an influential figure in the world of genomics, and through him, our understanding of this space has extended beyond Illumina. Flatley is now chair, and Acting CEO of Zymergen and serves as a member of the board of Denali Therapeutics Inc, both of which are held by Scottish Mortgage. Francis de Souza, the current CEO, is also a key figure in the Illumina story, passionately driving the company forward even further.
in March 2011.
Investment trusts are UK public companies and are not authorised and regulated by the Financial Conduct Authority. You may not get back the amount invested and please bear in mind that past performance is not a guide to future performance.